Soft Q2, but tide to turn in H2'25e

Sales miss, but orders rebound

Q3'24 results fast comment

Waiting for volume upturn

Cavotec SA: 1 director

A director at Cavotec SA bought 5,055,339 shares at 18.000SEK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Miss driven by P&M, but Industry improving

Weak Q1 but outlook remains solid

Q3'24 results fast comment

So far so good, but not done yet

A step in the right direction

Strong order intake and improved profitability

Q3'24 results fast comment

Awaiting order momentum

Profitability improvements, but lower orders

Seventh quarter of EBIT improvement

Q3'24 results fast comment

Ready to push the pedal on growth

Still room for improvement

Q2 sales EUR 42m, -7% y-o-y, order intake EUR 40m, +11% y-o-y. Minor adjustments to '24-'26 estimates. FCF positive, continued focus on working capital.

Margin improvements and positive FCF

Q1'24 results fast comment

Normalised growth but improving margin

Q2 report due on 25 July at 07:00 CEST. Q2e: sales EUR 42m, -7% y-o-y; EBIT margin of 4.2% (2.6%). Positive margin trends in PM, improvement areas defined in Industry.

Margins climb for fifth straight quarter

Q1: sales EUR 42m, +9% y-o-y, order intake EUR 40m, -5% y-o-y. We lower '24e-'26e sales and order intake by 6-10% and 4-6%. Keep margin estimates largely intact on improved profitability.

Margin improvements taking effect

Q1'24 results fast comment

Margin improvements ahead

Q1 report due Wednesday 15 May at 07:00 CEST. Q1e: sales EUR 44.2m, up 12% y-o-y; EBIT margin of 3.9% (0.8%). We expect positive margins, sales and cash flow trends to continue.

Cavotec SA - Increased confidence in H2 profitability

Strong backlog, growth in sales and break-even EBIT ‘22e EBIT up 2%, ‘23e-‘24e EBIT down 9-4% ‘24e EBIT 4x above ‘22e, 24% org. sales CAGR ‘22e-24e